Thrombosis Research
Volume 122 , Pages S3-S8 , 2008

Structure and activity of plasmin and other direct thrombolytic agents

References 

  1. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost. Jul 1995;74(1):429–436
  2. Lerch PG, Rickli EE, Lergier W, Gillessen D. Localization of individual lysine-binding regions in human plasminogen and investigation on their complex-forming properties. Eur J Biochem. 1980;107:7–13
  3. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem. 1983;258:4249–4256
  4. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem. 1978;84:573–582
  5. Moroi M, Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem. 1978;251:5956–5965
  6. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69:209–216
  7. Shulman S, Alkjaersig N, Sherry S. Physicochemical studies on human plasminogen (profibrinolysin) and plasmin (fibrinolysin). J Biol Chem. Jul 1958;233(1):91–97
  8. Back N, Ambrus JL, Goldstein S, Harrisson JW. In vivo fibrinolytic activity and pharmacology of various plasmin (fibrinolysin) preparations. Circ Res. Jul 1956;4(4):440–443
  9. Amris Cj, Larsen V, Mogensen B, Storm O. Clinical studies on an activator free porcine plasmin (plasmin-novo). Sangre (Barc). 1964;61:12–18
  10. Herndon RM, Meyer JS, Jophnson JF, Landers J. Treatment of cerebrovascular thrombosis with fibrinolysin. Am J Cardiol. 1960;6:540–545
  11. Ronwin E. Enzymatic properties of bovine plasmin preparations; evidence for similarity to but non-identity with trypsin. Can J Biochem Physiol. Nov 1956;34(6):1169–1183
  12. Verstraete M. The fibrinolytic system: from Petri dishes to genetic engineering. Thromb Haemost. Jul 1995;74(1):25–35
  13. Moser KM. Effects of intravenous administration of fibrinolysin (plasmin) in man. Circulation. 1959;20:42–55
  14. Ambrus JL, Ambrus CM, Sokal JE, et al. Clinical pharmacology of various types of fibrinolytic enzyme preparation. Am J Cardiol. 1960;6:462–475
  15. Cliffton EE. Review of clinical experience with clotlysing agents. Am J Cardiol. 1960;6:476–486
  16. Davis ND, Carroll BJ, Schwartz SH. Treatment of thrombophlebitis with a fibrinolytic agent. Am J Cardiol. 1960;6:513–518
  17. Egen NB, Russell FE, Sammons DW, et al. Isolation by preparative isoelectric focusing of a direct acting fibrinolytic enzyme from the venom of Agkistrodon contortrix contortrix (southern copperhead). Toxicon. 1987;25(11):1189–1198
  18. Deitcher SR, Funk WD, Buchanan J, et al. Alfimeprase: a novel recombinant direct-acting fibrinolytic. Expert Opin Biol Ther. Dec 2006;6(12):1361–1369
  19. Ouriel K, Cynamon J, Weaver FA, et al. A phase I trial of alfimeprase for peripheral arterial thrombolysis. J Vasc Interv Radiol. Aug 2005;16(8):1075–1083
  20. Moll S, Kenyon P, Bertoli L, et al. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J Clin Oncol. Jul 1 2006;24(19):3056–3060
  21. Shah AR, Scher L. Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic. Drugs. 2007;10:329–335
  22. Nuvelo Inc Press Release: Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development. March 17 2008. http://phx.corporate-ir.net/phoenix.zhtml?c=109749&p=irol-newsArticle&ID=1119462&highlight=.
  23. Nagai N, Demarsin E, Van Hoef B, et al. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost. 2003;1:307–313
  24. Komorowicz E, Kolev K, Machovich R. Fibrinolysis with des-kringle derivatives of plasmin and its modulation by plasma protease inhibitors. Biochemistry. 1998;37:9112–9118
  25. ThromboGenics NV announces update on its microplasmin development strategy for peripheral vascular disease. ThromboGenics NV. http://www.thrombogenics.com/documents/06_TG_10PAOD_DVTENGFINAL.pdf. August 28, 2007.
  26. Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci. Feb 2004;45(2):641–647
  27. Hunt J, Novokhatny V. Production and characterization of a novel, recombinantly-modified plasmin molecule. J Thromb Haemost. 2005;3(Suppl 1):P0781
  28. Hunt J, Petteway S, Scuderi P, et al. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with full-length plasmin. Thromb Haemost [In Press].
  29. Potter van Loon BJ, Rijken DC, Brommer EJ, van der Maas AP. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost. 1992;67:101–105
  30. Robbie LA, Bennett B, Croll AM, et al. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost. 1996;75:127–133
  31. Novokhatny V, Taylor K, Zimmerman TP. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost. May 2003;1(5):1034–1041
  32. Novokhatny VV, Jesmok GJ, Landskroner KA, et al. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?. Trends Pharmacol Sci. Feb 2004;25(2):72–75
  33. Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood. 2003;101(8):3002–3007
  34. Markland FS. Fibrolase, an active thrombolytic enzyme in arterial and venous thrombosis model systems. Adv Exp Med Biol. 1996;391:427–438
  35. Toombs CF. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis. Haemostasis. 2001;31:141–147
  36. VJ , Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost. 2001;86(3):739–745
  37. Shlansky-Goldberg RD, Matsumoto AH, Baumbach GA, Siegel JB, Raabe RD, Murphy TP, Deng C, Dawkins JR, Marder VJ. A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion. J Thromb Haemost 2008 Apr 2;in press.

PII: S0049-3848(08)00238-7

doi: 10.1016/j.thromres.2008.06.018

Thrombosis Research
Volume 122 , Pages S3-S8 , 2008

Article Tools

* Image Usage & Resolution